Fate Therapeutics Valuation
| FATE Stock | USD 0.94 0.03 3.30% |
Today, the firm appears to be overvalued. Fate Therapeutics shows a prevailing Real Value of $0.9 per share. The current price of the firm is $0.94. Our model computes the value of Fate Therapeutics from reviewing the firm fundamentals such as Shares Outstanding of 114.6 M, operating margin of (25.27) %, and Shares Owned By Insiders of 2.26 % as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Fate Therapeutics' price fluctuation is abnormally volatile at this time. Calculation of the real value of Fate Therapeutics is based on 3 months time horizon. Increasing Fate Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Fate stock is determined by what a typical buyer is willing to pay for full or partial control of Fate Therapeutics. Since Fate Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Fate Stock. However, Fate Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.94 | Real 0.9 | Hype 0.94 | Naive 1.16 |
The real value of Fate Stock, also known as its intrinsic value, is the underlying worth of Fate Therapeutics Company, which is reflected in its stock price. It is based on Fate Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Fate Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Fate Therapeutics helps investors to forecast how Fate stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Fate Therapeutics more accurately as focusing exclusively on Fate Therapeutics' fundamentals will not take into account other important factors: Fate Therapeutics Total Value Analysis
Fate Therapeutics is currently anticipated to have valuation of (88.31 M) with market capitalization of 103.78 M, debt of 85.27 M, and cash on hands of 568.85 M. The negative valuation of Fate Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Fate Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(88.31 M) | 103.78 M | 85.27 M | 568.85 M |
Fate Therapeutics Investor Information
About 90.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.33. Some equities with similar Price to Book (P/B) outperform the market in the long run. Fate Therapeutics recorded a loss per share of 1.64. The entity had not issued any dividends in recent years. Based on the key indicators related to Fate Therapeutics' liquidity, profitability, solvency, and operating efficiency, Fate Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Fate Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Fate Therapeutics has an asset utilization ratio of 3.09 percent. This indicates that the Company is making $0.0309 for each dollar of assets. An increasing asset utilization means that Fate Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Fate Therapeutics Ownership Allocation
Fate Therapeutics holds a total of 114.6 Million outstanding shares. The majority of Fate Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Fate Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Fate Therapeutics. Please pay attention to any change in the institutional holdings of Fate Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Fate Therapeutics Profitability Analysis
The company reported the previous year's revenue of 13.63 M. Net Loss for the year was (186.26 M) with loss before overhead, payroll, taxes, and interest of (104.9 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Fate Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Fate Therapeutics and how it compares across the competition.
About Fate Therapeutics Valuation
The stock valuation mechanism determines Fate Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Fate Therapeutics. We calculate exposure to Fate Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Fate Therapeutics's related companies.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Fate Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 542 people.
Fate Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Fate Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 113.7 M |
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |